Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Arcturus Therapeutics Holdings Inc.
Headquarters: San Diego, CA, United States of America
Website: http://arcturusrx.com
Year Founded: 2013
Status: Public
Industry Sector: HealthTechnology
CEO: Joseph E. Payne
Number Of Employees: 176
Enterprise Value: $194,712,004
PE Ratio: -3.16
Exchange/Ticker 1: NASDAQ:ARCT
Exchange/Ticker 2: N/A
Latest Market Cap: $257,231,296
BioCentury | Mar 4, 2025
Management Tracks
Head of R&D Robert Lenz to leave Neumora
Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more
BioCentury | Feb 6, 2025
Management Tracks
Arcturus appoints Slaoui chair designate
Plus: Affinia hires Makimura and Xu joins Sciwind
BioCentury | Dec 14, 2024
Data Byte
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP
November meeting highlights also include a pair of firsts for rare genetic diseases, and label expansions for eight approved drugs
BioCentury | May 29, 2024
Deals
Deals Report: Three $1B+ takeouts highlight demand in immunology, renal
Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more
BioCentury | Aug 15, 2023
Deals
Aug. 14 Quick Takes: Second bidder drove up price in Biogen-Reata deal
Plus: Approval for Pfizer’s MM bispecific and updates from Harmony-Zynerba, One Bio-Hengrui, Taysha, Arcturus, BioXcel
BioCentury | Jun 24, 2023
Discovery & Translation
ROTACs for transmembrane protein degradation; plus AntlerA’s lung regeneration therapy and more
BioCentury’s roundup of translational news
BioCentury | Nov 3, 2022
Deals
Nov. 2 Quick Takes: CSL paying $200M for Arcturus’ mRNA vaccine tech
Plus Rubius seeking alternatives and updates from Horizon, Lilly-Innovent, GSK, Compass, Regeneron, Exelixis, CFIUS and more
BioCentury | Apr 21, 2022
Product Development
April 20 Quick Takes: AbbVie steps away from another alpha-synuclein program
Plus: Arcturus falls on efficacy data for COVID-19 vaccine, and updates from Dragonfly, I-Mab, Windtree and Oncomatryx
BioCentury | Mar 1, 2022
Management Tracks
Jones leaving BMS to become CMO of Cullinan
Plus Singleton to join Bioventus as CFO, and updates from Noema, Lycia, Avidity and more
BioCentury | Jan 25, 2022
Management Tracks
Braunstein now CMO at Idorsia
Plus Kush, Haddach join RayzeBio and updates from Coherus, InterVenn, AsherBio and more
Items per page:
1 - 10 of 26